Mianserin
As of the edition of 20 October 2026, Mianserin is a small molecule: marketed, first approved in 1979 (ES); acts on HTR2A, HTR2B and HTR2C.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1979
- Kind
- Small molecule
- Brand name
- Lantanon
- First approved
- 1 January 1979 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Organon Salud S.L.
- Withdrawn from market
- 1 January 1986 (in some regions)
- Registered trials
- 2, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 2 |